ArticleJournal of biological engineering2025
Synthetic redesign of Corynebacterium glutamicum for 1,4-butanediol production via L-glutamate-derived CoA-independent pathway.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in pathway engineering for the biosynthesis of 1,4-butanediol.Applied microbiology and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
1,4-Butanediol (1,4-BDO) is a key commodity chemical used in the production of various products, including plastics, fibers, and polyesters. Here, a potent microbial platform for 1,4-BDO production from glucose via the L-glutamate-derived CoA-independent pathway was developed using Corynebacterium glutamicum as the host strain. Introducing a CoA-independent 1,4-BDO biosynthesis pathway and removing a metabolic flux bypass, the resulting initial strain produced 2.20 g/L of 1,4-BDO from glucose. Upon prolonged cultivation, C. glutamicum showed an endogenous capacity to degrade 1,4-BDO. Transcriptomic analysis was conducted to identify genes potentially involved in this pathway. Among them, fadH, aldH, and adhA were verified as the key enzymes for 1,4-BDO degradation. The deletion of three dehydrogenase genes from the initial strain removed the product degradation and achieved an improved 1,4-BDO titer of 3.14 g/L. Finally, fed-batch fermentation of the final strain was conducted, resulting in 13.4 g/L of 1,4-BDO production. This work demonstrates the first successful development of C. glutamicum as a potent platform strain for the biosynthesis of 1,4-BDO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.